NCT01226407View on ClinicalTrials.gov

Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile

PHASE1UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Solid Tumour
Interventions
DRUG

CG200745

Multiple administration (IV) over the cycles untile MTD/LTD

Trial Locations (1)

138-736

RECRUITING

Seoul Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

CrystalGenomics, Inc.

INDUSTRY